MyFinsight
Home
Blog
About
Net increase in
cash, cash...
-$195,513K
(-913.21%↓ Y/Y)
something is missing
$15,000K
Accrued liabilities
$6,329K
Accounts payable
$2,706K
(157.94%↑ Y/Y)
Accrued compensation
$1,871K
(-87.34%↓ Y/Y)
Stock-based compensation
expense
$893K
(-97.48%↓ Y/Y)
Other long-term
liabilities
$775K
Non-cash operating lease
costs
$754K
(-54.16%↓ Y/Y)
Depreciation
$343K
(-78.55%↓ Y/Y)
Net cash used in
investing activities
-$191,587K
(-155.91%↓ Y/Y)
Net cash used in
operating activities
-$3,926K
(98.79%↑ Y/Y)
Canceled cashflow
$28,671K
Purchases of short-term
investments
$191,551K
(-21.26%↓ Y/Y)
Purchases of property and
equipment
$36K
(-99.49%↓ Y/Y)
Net loss
-$20,186K
(92.61%↑ Y/Y)
Other current assets
$6,232K
Deferred revenues
-$3,004K
(44.58%↑ Y/Y)
Prepaid assets
$1,928K
(-98.34%↓ Y/Y)
Lease liabilities
-$997K
(48.05%↑ Y/Y)
Amortization of premiums and
discounts on short-term...
$250K
(-97.10%↓ Y/Y)
Back
Back
Cash Flow
Atrium Therapeutics, Inc. (RNA)
Atrium Therapeutics, Inc. (RNA)
source: myfinsight.com